Article published Jul 13, 2026. Prices below use latest available snapshots.
hot-take · self
The funding-cycle rotation is confirmed. Biotech dominated the 30-day movers list, and the tools-and-CRO cohort is up across the board — CRL +24%, ABCL +29%, TWST +22%, IQV +15%, ILMN +14%, MEDP +13%, TMO +11%, DHR +10% — a month after the June read that the rotation was "already underway and bifurcated."
The bifurcation is now the whole story. The fast tier — TXG +47%, ABSI +63% — ran hardest, and the tape marks that leg exhausted: TXG at RSI 72 on 0.82× relative volume, KYMR at RSI 71 on 0.50×, DFTX on 0.53×. Every stretched name in the universe right now is climbing on thinning volume; not one qualifies as a healthy volume-backed move. These are late-stage parabolas, and RSI 80 is not an entry.
Which makes the actionable question a ladder, not a chase. The theme has two expressions and they want different treatment:
- The tools-and-CRO tier is the supported trade — double-digit gains with no name on the exhaustion screen, and a hard catalyst ahead. It is the tier where being long already works.
- The mid-cap tier needs a written trigger. KYMR, RARE, VKTX and AGIO (+36–44%) are mid-cap therapeutics with real programs and profitable-or-near financials — legitimate expressions of the same theme, currently too extended to touch. The entry condition worth writing down, for these and for TXG/ABSI when this leg exhausts: a base, a reclaim of a rising average, and volume confirmation. A trigger converts the next run from a spectator event into a yes-or-no at a level.
Next read: MEDP Q2 book-to-bill, late this month — the domino the whole funding-cycle theme has been waiting on since June. If the CROs confirm, the funding gate is open and the mid-cap triggers start mattering fast.
Prices, RSI, relative volume and 30-day moves from an internal tape refresh (data as of the 2026-07-10 close). Cohort membership and the June "extended mid-cap" verdict per the biotech-capital-cycle roster and its 2026-06-04 thesis record.